Tesamorelin is a synthetic analog of growth hormone–releasing hormone (GHRH). In some regions it has regulatory approval for specific HIV-associated indications related to excess visceral adipose tissue.

Beyond labeled indications, tesamorelin appears in broader metabolic and body- composition discussions, though such uses may not be supported to the same evidentiary or regulatory standard.

Tesamorelin binds to GHRH receptors in the pituitary, stimulating endogenous growth hormone secretion and, downstream, influencing IGF-1 and metabolic pathways. Its effects on body composition and lipid metabolism are thought to be mediated through these GH/IGF-1–related mechanisms.

The pattern and magnitude of response can vary with dose, duration, and baseline GH-axis function, as well as with comorbid conditions such as HIV infection.

In regions where tesamorelin is approved, labeled indications focus on specific HIV-associated changes in visceral adipose tissue. Use is typically guided by infectious disease and endocrine specialists.

Outside these indications, tesamorelin may be discussed in relation to general obesity, metabolic risk, or body composition. Such uses should be evaluated carefully against local regulations, available evidence, and the balance of potential risks and benefits.

Reported side effects include injection-site reactions, arthralgia, peripheral edema, and changes in glucose tolerance in some individuals. Because it modulates GH and IGF-1, there is ongoing interest in long-term safety, particularly in populations with existing metabolic or cardiovascular risk.

Clinician oversight, appropriate patient selection, and regular monitoring are essential parts of safe use.

Tesamorelin is a GHRH analog with a specific clinical approval for visceral fat reduction in HIV-associated lipodystrophy.

This information is based on the FDA-approved labeling for Egrifta.

Commercial tesamorelin products are typically supplied as kits with lyophilized powder and diluent. In some catalogs, structurally similar peptides may be listed for research or wellness markets.

Structural listings in this catalog highlight vial codes and specifications and should not be interpreted as endorsements of specific sources or combinations.

Clinical trials of tesamorelin in HIV-associated lipodystrophy have examined endpoints such as visceral fat volume, metabolic markers, and quality of life. Additional research explores broader metabolic effects and durability of response.

As evidence accumulates, questions remain about long-term outcomes, optimal patient selection, and how tesamorelin compares with other interventions. High-level educational summaries should be paired with direct review of primary data when making clinical decisions.

Future FAQs may discuss how tesamorelin differs conceptually from GH therapy and other GHRH analogs, how clinicians evaluate benefits and risks in people with HIV, and what kinds of monitoring are typically used. Answers will remain educational and non-prescriptive.